exRNAdisease

Entry Detail

---



General Information

Database ID: exR0087666 RNA Name: hsa-miR-1252-5p RNA Type: miRNA Chromosome: chr12 Starnd: + Coordinate: Start Site(bp): 79419261 End Site(bp): 79419282 External Links: hsa-miR-1252-5p

Disease Information

Disease Name: Breast Cancer Disease Category: Cancers MeSH ID: D001943 Type: Neoplasms/Breast Neoplasms Alias: Breast Neoplasms//Breast Neoplasm//Neoplasm, Breast//Breast Tumors//Breast Tumor//Tumor, Breast//Tumors, Breast//Neoplasms, Breast//Breast Cancer//Cancer, Breast//Mammary Cancer//Cancer, Mammary//Cancers, Mammary//Mammary Cancers//Malignant Neoplasm of Breast//Breast Malignant Neoplasm//Breast Malignant Neoplasms//Malignant Tumor of Breast//Breast Malignant Tumor//Breast Malignant Tumors//Cancer of Breast//Cancer of the Breast//Mammary Carcinoma, Human//Carcinoma, Human Mammary//Carcinomas, Human Mammary//Human Mammary Carcinomas//Mammary Carcinomas, Human//Human Mammary Carcinoma//Mammary Neoplasms, Human//Human Mammary Neoplasm//Human Mammary Neoplasms//Neoplasm, Human Mammary//Neoplasms, Human Mammary//Mammary Neoplasm, Human//Breast Carcinoma//Breast Carcinomas//Carcinoma, Breast//Carcinomas, Breast

Expression Detail

GEO ID: GSE101841 Description: Serum microRNA profile of Her2 positive metastatic breast cancer patients Experimental Design: Trastuzumab therapy Case Disease Type: Breast Cancer Case Disease SubType: HER2 positive metastatic breast cancer Case Sample: Breast Cancer Trastuzumab resistant Control Sample: Trastuzumab sensitive Number of Case: 42 Number of Control: 61 Number of Samples: 103

Regulatory Relationship

mRNA targets: NA miRNA targets: NA circRNA targets: circRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand hsa_circ_0001605 chr6 42903447 42905047 + hsa_circ_0001495 chr5 68470703 68471364 + hsa_circ_0001146 chr20 34241449 34246936 - lncRNA targets: lncRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand AC002467.1 chr7 107739999 107744581 - AC005034.3 chr2 75697583 75697996 + AC007952.4 chr17 19112000 19112636 - AC011498.2 chr19 4447304 4448217 + AC067930.1 chr8 143579636 143580670 + AL590617.2 chr6 138692548 138697288 + BX284668.2 chr1 16870945 16883659 + KCNQ1OT1 chr11 2608328 2699994 - LINC01128 chr1 825138 859446 + LINC01278 chrX 63222993 63561095 - LINC01783 chr1 16533886 16536172 - MALAT1 chr11 65497688 65506516 + MIR17HG chr13 91347820 91354579 + NEAT1 chr11 65422774 65445540 + OIP5-AS1 chr15 41283990 41309737 + SNHG15 chr7 44983023 44986961 - XIST chrX 73820649 73852723 - Display:

Experiment Detail

GEO ID: GSE101841 Sample Source: Blood Source Fraction: Serum Platform: GPL23138 Method: Microarray Num of detected RNA Type: 1 Num of detected RNAs of this Type: 1808 Sample treatment protocol: NA RNA Extract protocol: Total RNA was extracted from 103 samples with the Plasma RNA Purification Mini Kit (51000, NorgenBiotek Corporation, Canada), following manufacturer's instructions. RNA library preparation protocol: Total RNA extracted from 600ul serum was employed with 100 nmol/L of pCp-DY647 and 15 Units of T4 RNA ligase in a total reaction volume of 20 ul at 16°C overnight.

Reference

PMID: 29691399 Title: A serum microRNA signature predicts trastuzumab benefit in HER2-positive metastatic breast cancer patients. Author: Li H, Liu J, Chen J, Wang H, Yang L, Chen F, Fan S, Wang J, Shao B, Yin D, Zeng M, Li M, Li J, Su F, Liu Q, Yao H, Su S, Song E Journal: Nat Commun. 2018 Apr 24;9(1):1614. Description: MicroRNAs (miRNAs) have been used to predict therapeutic effects for various cancers, but whether miRNAs can serve as biomarkers for HER2+ metastatic breast cancer (MBC) patients remains unclear.